{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+therapy+%28Including+Immunosuppressants%29&page=2", "query": { "intervention": "Standard therapy (Including Immunosuppressants)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 26, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+therapy+%28Including+Immunosuppressants%29&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+therapy+%28Including+Immunosuppressants%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-11T11:59:03.839Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06859424", "title": "A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "AML (Acute Myelogenous Leukemia)", "Acute Lymphoid Leukemia (ALL)", "Acute Leukemia (Category)", "MDS (Myelodysplastic Syndrome)", "CML (Chronic Myelogenous Leukemia)", "CLL (Chronic Lymphocytic Leukemia)", "Prolymphocyctic Leukemia", "Chronic Myelomonocytic Leukemia (CMML)", "Myeloproliferative Neoplasm (MPN)", "Lymphoma", "Myelofibrosis" ], "interventions": [ { "name": "Conditioning Regimen A", "type": "DRUG" }, { "name": "Conditioning Regimen B", "type": "DRUG" }, { "name": "Conditioning Regimen C", "type": "DRUG" }, { "name": "Conditioning Regimen D", "type": "DRUG" }, { "name": "Conditioning Regimen E", "type": "DRUG" }, { "name": "Hematopoietic Cell Transplantation", "type": "PROCEDURE" }, { "name": "PTCy (50 mg/kg D3, D4)", "type": "DRUG" }, { "name": "PTCy (25 mg/kg D3, D4)", "type": "DRUG" }, { "name": "Post-transplant Tacrolimus", "type": "DRUG" }, { "name": "Post-transplant Mycophenolate mofetil", "type": "DRUG" }, { "name": "Post-transplant Abatacept", "type": "DRUG" }, { "name": "Post-transplant Ruxolitinib", "type": "DRUG" }, { "name": "Supportive Care: Growth Factors", "type": "DRUG" }, { "name": "Supportive Care: Blood Products", "type": "PROCEDURE" }, { "name": "Supportive Care: Infection Prophylaxis", "type": "OTHER" }, { "name": "Supportive Care: Intravenous immune globulin (IVIG)", "type": "OTHER" }, { "name": "Supportive Care: Seizure prophylaxis", "type": "DRUG" }, { "name": "Supportive Care: Monitoring and management of CRS", "type": "OTHER" }, { "name": "Supportive Care: Prophylaxis against infections", "type": "OTHER" }, { "name": "Supportive Care: Prophylaxis against infections", "type": "DRUG" }, { "name": "Supportive Care: Lipid elevations", "type": "OTHER" }, { "name": "Study treatment compliance", "type": "OTHER" }, { "name": "Prohibited Concomitant Therapy", "type": "OTHER" }, { "name": "Permitted Concomitant Therapy", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "Center for International Blood and Marrow Transplant Research", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "66 Years", "sex": "ALL", "summary": "18 Years to 66 Years" }, "enrollment_count": 358, "start_date": "2025-07-25", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2026-03-17", "last_synced_at": "2026-10-11T11:59:03.839Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Westwood", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06859424" }, { "nct_id": "NCT03656926", "title": "Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bronchiolitis Obliterans", "Chronic Rejection of Lung Transplant", "Lung Transplant Rejection", "Lung Transplant; Complications", "Lung Transplant Failure and Rejection", "Chronic Lung Allograft Dysfunction" ], "interventions": [ { "name": "Liposomal Cyclosporine A", "type": "DRUG" }, { "name": "Standard of Care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Zambon SpA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 169, "start_date": "2019-03-26", "completion_date": "2024-03-12", "has_results": true, "last_update_posted_date": "2026-02-10", "last_synced_at": "2026-10-11T11:59:03.839Z", "location_count": 21, "location_summary": "Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03656926" }, { "nct_id": "NCT00027560", "title": "Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms" ], "interventions": [ { "name": "alemtuzumab", "type": "BIOLOGICAL" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "70 Years", "sex": "ALL", "summary": "Up to 70 Years" }, "enrollment_count": 51, "start_date": "2001-07", "completion_date": "2009-04", "has_results": true, "last_update_posted_date": "2013-01-07", "last_synced_at": "2026-10-11T11:59:03.839Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00027560" }, { "nct_id": "NCT03657342", "title": "Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bronchiolitis Obliterans", "Chronic Rejection of Lung Transplant", "Lung Transplant Rejection", "Lung Transplant; Complications", "Lung Transplant Failure and Rejection", "Chronic Lung Allograft Dysfunction" ], "interventions": [ { "name": "Liposomal Cyclosporine A", "type": "DRUG" }, { "name": "standard of care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Zambon SpA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2019-03-26", "completion_date": "2024-04-16", "has_results": true, "last_update_posted_date": "2025-10-27", "last_synced_at": "2026-10-11T11:59:03.839Z", "location_count": 25, "location_summary": "Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03657342" }, { "nct_id": "NCT01860963", "title": "Anal Dysplasia in Patients With Inflammatory Bowel Disease and Healthy Controls", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Anal Squamous Intraepithelial Lesion (ASIL)", "HPV DNA" ], "interventions": [ { "name": "Anal Pap smear and HPV DNA testing", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 310, "start_date": "2010-01", "completion_date": "2013-06", "has_results": false, "last_update_posted_date": "2013-10-01", "last_synced_at": "2026-10-11T11:59:03.839Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01860963" }, { "nct_id": "NCT07762703", "title": "Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Triple-Negative Breast Cancer (TNBC)" ], "interventions": [ { "name": "BreakVax", "type": "DRUG" }, { "name": "Ipilimumab 2.5 mg", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Standard-of-care chemotherapy", "type": "DRUG" }, { "name": "Losartan and aspirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BreakBio Corp", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "72 Years", "sex": "ALL", "summary": "18 Years to 72 Years" }, "enrollment_count": 10, "start_date": "2026-09", "completion_date": "2030-09", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-10-11T11:59:03.839Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07762703" }, { "nct_id": "NCT03312907", "title": "A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "Belimumab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Rituximab-placebo", "type": "DRUG" }, { "name": "Standard therapy (Including Immunosuppressants)", "type": "DRUG" }, { "name": "Standard therapy (Excluding Immunosuppressants)", "type": "DRUG" }, { "name": "Steroid Taper", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 292, "start_date": "2018-03-01", "completion_date": "2021-07-07", "has_results": true, "last_update_posted_date": "2025-02-18", "last_synced_at": "2026-10-11T11:59:03.839Z", "location_count": 28, "location_summary": "Birmingham, Alabama • La Mesa, California • San Leandro, California + 22 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Mesa", "state": "California" }, { "city": "San Leandro", "state": "California" }, { "city": "Upland", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03312907" }, { "nct_id": "NCT03277703", "title": "Flu Vaccine Response in Patients on Biologic Therapies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatologic Disorder", "Inflammatory Bowel Diseases", "Immune Complex Diseases" ], "interventions": [ { "name": "Influenza vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Stony Brook University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "22 Years", "sex": "ALL", "summary": "3 Years to 22 Years" }, "enrollment_count": 30, "start_date": "2017-11-03", "completion_date": "2019-12-30", "has_results": true, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-10-11T11:59:03.839Z", "location_count": 1, "location_summary": "East Setauket, New York", "locations": [ { "city": "East Setauket", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03277703" }, { "nct_id": "NCT03393013", "title": "A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lupus Nephritis", "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "KZR-616", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kezar Life Sciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 69, "start_date": "2018-02-20", "completion_date": "2022-08-04", "has_results": true, "last_update_posted_date": "2025-11-18", "last_synced_at": "2026-10-11T11:59:03.839Z", "location_count": 17, "location_summary": "Los Angeles, California • Upland, California • Miami, Florida + 12 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Upland", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03393013" }, { "nct_id": "NCT05400122", "title": "Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Hematologic Malignancy", "Rectum Cancer", "Acute Myeloid Leukemia", "Myelodysplastic Syndromes", "Acute Lymphoblastic Leukemia", "Chronic Myeloid Leukemia", "Chronic Lymphocytic Leukemia", "Hodgkin Lymphoma", "Non Hodgkin Lymphoma", "Myeloproliferative Syndrome", "Plasma Cell Myeloma", "Gastric Cancer", "Esophageal Cancer", "Esophagus Cancer", "Gastric Cancer, Metastatic", "Unresectable Esophageal Cancer", "Metastatic Esophageal Cancer" ], "interventions": [ { "name": "Vactosertib", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "IL-2", "type": "DRUG" }, { "name": "Natural Killer Cells", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "David Wald", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2022-09-09", "completion_date": "2027-06-01", "has_results": false, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-10-11T11:59:03.839Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05400122" } ] }